Cue Biopharma Competitors and Similar CompaniesClear all
Cue Biopharma's competitors and similar companies include Sorrento Therapeutics, Catalyst Pharmaceuticals, Momenta Pharmaceuticals and Alnylam.
 Cue Biopharma Cue Biopharma is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. |  Momenta Pharmaceuticals Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | |
Founding Date | Founding Date 2015 | Founding Date 2006 | Founding Date 2002 | Founding Date 2001 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Cambridge, US HQ | Locations San Diego, US HQ San Diego, US | Locations Coral Gables, US HQ | Locations Cambridge, US HQ Dublin, IE Cambridge, US | |
Employees | Employees 4664% increase | Employees 31019% decrease | Employees 7649% increase | Employees 761% decrease | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 107.3 m | Valuation ($) 1.5 m | Valuation ($) 2.6 b | Valuation ($) N/A | Valuation ($) 36.5 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $9.3m (FY, 2024) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $491.7m (FY, 2024) | Revenue (est.) $23.9m (FY, 2019) | Revenue (est.) $2.2b (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $68.8m (FY, 2024) | Cost of goods N/A | Cost of goods $306.5m (FY, 2024) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $422.9m (FY, 2024) | Gross profit N/A | Gross profit $1.9b (FY, 2024) |
Net income | Net income ($40.7m) (FY, 2024) | Net income ($577.8m) (FY, 2022) | Net income $163.9m (FY, 2024) | Net income ($290.1m) (FY, 2019) | Net income ($278.2m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 42.6m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
Sorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyCatalyst Pharmaceuticals
HQ
Coral Gables, US
Employees
76↑ 49% increase
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.
View companyMomenta Pharmaceuticals
HQ
Cambridge, US
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company